
Viridian Therapeutics (VRDN) Stock Forecast & Price Target
Viridian Therapeutics (VRDN) Analyst Ratings
Bulls say
Viridian Therapeutics is positioned for a positive financial outlook due to its innovative product, Veligrotug, which shows promising clinical results in treating thyroid eye disease, including proptosis reduction and improvement in patient quality of life. The company's development of VRDN-003 for subcutaneous administration is expected to enhance its market presence and competitive advantage, leading to increased market share in the therapy for thyroid eye disease. Furthermore, successful clinical execution and regulatory progress are anticipated to boost investor confidence and support potential commercial launches, driving future growth and valuation increases.
Bears say
The financial outlook for Viridian Therapeutics Inc. is considerably negative due to the potential delays in the launch of its lead product candidate, Veligrotug, which could result in a valuation decrease of approximately $4 per share if postponed by a year. Additionally, the risk of ineffective results from the REVEAL studies could remove VRDN-003 from estimates, leading to a substantial $14 per share reduction and reflecting a 30% downside risk to the company. Compounding these challenges, the threat of competition from well-capitalized industry players along with concerns related to intellectual property protection and management execution further diminishes Viridian's market positioning and long-term profitability prospects.
This aggregate rating is based on analysts' research of Viridian Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Viridian Therapeutics (VRDN) Analyst Forecast & Price Prediction
Start investing in Viridian Therapeutics (VRDN)
Order type
Buy in
Order amount
Est. shares
0 shares